Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
1.850
-0.010 (-0.54%)
At close: Apr 28, 2026, 4:00 PM EDT
1.877
+0.027 (1.47%)
After-hours: Apr 28, 2026, 6:12 PM EDT
Milestone Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Milestone Pharmaceuticals stock have an average target of 8.00, which predicts an increase of 332.43% from the current stock price of 1.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 6, 2026.
Analyst Ratings
The average analyst rating for Milestone Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +332.43% | Jan 6, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $4 → $8 | Buy | Maintains | $4 → $8 | +332.43% | Dec 16, 2025 |
| TD Cowen | TD Cowen | Hold → Strong Buy Upgrades $8 | Hold → Strong Buy | Upgrades | $8 | +332.43% | Dec 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $8 | Strong Buy | Maintains | $5 → $8 | +332.43% | Dec 15, 2025 |
| Wells Fargo | Wells Fargo | Buy Initiates $4 | Buy | Initiates | $4 | +116.22% | Sep 11, 2025 |
Financial Forecast
Revenue This Year
46.61M
from 1.55M
Increased by 2,915.14%
Revenue Next Year
29.72M
from 46.61M
Decreased by -36.25%
EPS This Year
-0.53
from -0.75
EPS Next Year
-0.87
from -0.53
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 87.7M | 42.0M | ||||||
| Avg | 46.6M | 29.7M | ||||||
| Low | 3.9M | 20.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 5,571.1% | -9.9% | ||||||
| Avg | 2,915.1% | -36.2% | ||||||
| Low | 153.6% | -55.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | -0.06 | -0.67 | ||||
| Avg | -0.53 | -0.87 | ||||
| Low | -1.13 | -1.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.